Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Alectinib for First-Line Treatment in NSCLC with ALK Mutation

TOP - November 2016, Vol 9, No 4 - Conference Correspondent
Wayne Kuznar

New data from an interim analysis of the head-to-head, open-label, phase 3, Japanese study J-ALEX, show that alectinib (Alecensa) significantly improved progression-free survival (PFS) compared with crizotinib (Xalkori) in the frontline setting, according to Hiroshi Nokihara, MD, PhD, of the National Cancer Center Hospital, Tokyo, Japan.

“Based on these results, we believe that alectinib is the new standard first-line therapy for ALK-positive NSCLC,” Dr Nokihara said recently.

Alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, was approved in December 2015 for advanced, ALK-positive non–small-cell lung cancer (NSCLC) that progressed after crizotinib therapy.

Overall, 207 Japanese patients with advanced or recurrent NSCLC and ALK mutation who had never received an ALK inhibitor were randomized to alectinib 300 mg twice daily or to crizotinib 250 mg twice daily, with a follow-up of 12 months in the alectinib group and 12.2 months in the crizotinib group. Treatment continued until disease progression or unacceptable toxicity. The primary end point was median PFS.

At baseline, 27.9% of patients in the crizotinib group had brain metastases compared with 13.6% in the alectinib group; other baseline characteristics were similar between the 2 groups.

The median PFS was significantly superior with alectinib versus crizotinib: at the time of data analysis, median PFS had not been reached with alectinib versus 10.2 months with crizotinib.

In patients with brain metastases at baseline, the hazard ratio for PFS was 0.08 with alectinib versus crizotinib.

Overall, 26.2% of patients in the alectinib group had grade 3 or 4 adverse events versus 51.9% in the crizotinib group. Treatment interruption because of adverse events was less common with alectinib (29.1%) than with crizotinib (74.0%).

The only adverse event reported in >30% of patients in the alectinib group was constipation; nausea, diarrhea, vomiting, visual disturbance, dysgeusia, constipation, elevation in alanine aminotransferase levels, and elevation in aspartate aminotransferase levels each occurred in >30% of patients.

Overall, 8 patients in each treatment group withdrew from the study because of interstitial lung disease.

Related Items
Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management
Wayne Kuznar
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in NCCN 2019 Conference, Pain Management
First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors
Wayne Kuznar
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Immunotherapy
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk MDS
Wayne Kuznar
TON - April 2019, Vol 12, No 2 published on April 22, 2019
Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer
Wayne Kuznar
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Colorectal Cancer
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Leukemia
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Immunotherapy
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Lynch Syndrome
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018, ONS Conference News
Last modified: January 9, 2017